Creative Medical Technology Holdings, Inc. acquires BioDefense, Inc. (2026)

Deal facts

Buyer: Creative Medical Technology Holdings, Inc.
Target: BioDefense, Inc.
Deal value: Not disclosed
Announced: 25 September 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, shares

Sources

What we know

Creative Medical Technology Holdings, Inc. has agreed to acquire a minority stake in BioDefense, Inc. The transaction was announced on 25 September 2026 and completed on 24 September 2026. Both companies are based in the United States and operate within the healthcare sector. The consideration for this deal consists of a combination of cash and shares. The specific financial value of the transaction has not been disclosed. This acquisition represents a strategic investment by Creative Medical Technology Holdings, Inc. in BioDefense, Inc., allowing the buyer to gain a partial ownership position without assuming full control of the target entity. The deal structure facilitates a partnership between the two US-based healthcare firms. No further details regarding the percentage of equity acquired or specific operational changes resulting from the investment have been provided in the available data. The completion of this transaction marks the finalisation of the agreed terms between the parties. The transaction is now complete.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

24 Sept 2026CompletedClosed
Creative Medical Technology Holdings, Inc. completes acquisition of BioDefense, Inc.
Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Creative Acquisition Corp. (“CAC”), pursuant to which the Company purchased 4,000,000 shares of common stock of BioDefense, Inc. (“BioDefense”) from CAC for an aggregate purchase price consist
Source

OpinionExit Mode editorial

The healthcare sector rarely offers a pure play on defensive biotech without significant capital risk. Creative Medical Technology Holdings, Inc. has moved to acquire a minority stake in BioDefense, Inc., a transaction that closed on 25 September 2026. The consideration was a mix of cash and shares, a structure that signals a strategic partnership rather than a full exit. For the SME founder, this deal type is often overlooked in favor of full acquisitions, yet it carries distinct advantages for liquidity and strategic alignment. We see this as a pragmatic route for founders who wish to retain operational control while tapping into a larger corporate ecosystem.

The use of both cash and equity in the consideration is a critical mechanic here. Cash provides immediate liquidity, reducing the founder’s personal financial exposure. Shares, however, align long-term interests and create a vested stake in the buyer’s broader success. This hybrid approach is common in minority investments where the target company is not yet ready for a full buyout or where the buyer prefers to limit upfront cash outlay. It also implies that the target company, BioDefense, Inc., likely retains its independent board and operational autonomy, a point of leverage for any founder negotiating similar terms.

Regulatory context matters, even in minority stakes. While this is a US-to-US healthcare transaction, the sector is heavily scrutinized. Any change in control, even partial, can trigger reviews under antitrust laws if the combined entity’s market power crosses certain thresholds. The CMA in the UK or the FTC in the US may examine whether the stake grants the buyer undue influence over pricing or supply chains. Founders must be aware that even minority positions can attract regulatory attention if they confer significant voting rights or board seats. This is not a deal that slips under the radar simply because it is not a full acquisition.

The strategic signal here is clear: large healthcare players are diversifying into bio-defense capabilities without the full integration burden of a merger. This creates a window for specialized SMEs to secure strategic capital without surrendering full control. The completed status of the deal confirms that the parties navigated the necessary approvals and closings successfully. For the founder reader, this demonstrates that minority stakes are a viable exit path, particularly in niche healthcare sectors where full valuations may be difficult to justify.

This week, review your cap table and board composition. If you are in a specialized healthcare or biotech niche, identify potential strategic partners who might value a minority stake. Prepare a data room that highlights your operational independence and regulatory compliance. A minority stake deal requires proof that you can operate autonomously while delivering strategic value. Start that preparation now, as the window for such deals is open and the competition for strategic capital is intensifying.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More minority stake deals More from Creative Medical Technology Holdings, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

6 October 2026CompletedHealthcare

Live Oak Health LLC to acquire Adia Labs LLC

Live Oak Health LLC has agreed to acquire a minority stake in Adia Labs LLC. The transaction, which was completed on 30 September 2026, involved a total equity value of…

Buyer: Live Oak Health LLC
Target: Adia Labs LLC
Deal value: USD 1,500,000
Deal type: minority stake

Read deal Healthcare deals minority stake deals United States deals

22 May 2026Possible offerHealthcare

company owned by Luis Collantes to acquire Creo Medical SL

A company owned by Luis Collantes has agreed to acquire a minority stake in Creo Medical SL, a healthcare business based in Spain. The transaction involves cash consider…

Buyer: company owned by Luis Collantes
Target: Creo Medical SL
Deal value: Not disclosed
Deal type: minority stake

Read deal Healthcare deals minority stake deals Spain deals

23 December 2025CompletedHealthcare

YA II PN, LTD to acquire JUPITER NEUROSCIENCES, INC.

YA II PN, LTD and JUPITER NEUROSCIENCES, INC. entered the Exit Mode archive.

Buyer: YA II PN, LTD
Target: JUPITER NEUROSCIENCES, INC.
Deal value: USD 1,860,000
Deal type: minority stake

Read deal Healthcare deals minority stake deals United States deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

14 October 2026Firm intentionHealthcare

Laboratory Corporation of America Holdings to acquire BioReference Health, LLC

Laboratory Corporation of America Holdings has agreed to acquire BioReference Health, LLC in a transaction valued at 722 million US dollars. The deal, announced on 14 Oc…

Buyer: Laboratory Corporation of America Holdings
Target: BioReference Health, LLC
Deal value: USD 722,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

Buyer history